Sangamo ex vivo treatment increases resistance to HIV/AIDS infection
This article was originally published in Scrip
Exciting news from the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): a Californian biotech company has demonstrated that a drug-like non-vaccine treatment of immune cells from HIV/AIDS patient can be used to confer resistance to HIV/AIDS infection to patients previously not resistance to the virus, and that resistance can enable patients to reduce viral load to undetectable levels even in the absence of other anti-retroviral therapy.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.